BIRC5 and hepatocellular carcinoma: In mouse models with orthotopic HCC xenograft, the LBP‐delivered CRISPR system performed 26.4% editing efficiency at survivin oncogene, thus inhibiting tumor growth and metastasis (Figure 11D,E).